Zebrafish journal publishes cancer biology special issue
|
|
The zebrafish, a translucent fish often used as a model of human development and disease, offers unique advantages for studying the cause, growth, and spread of tumors using strategies and methods presented in the current “Cancer Biology” special issue of Zebrafish, a peer-reviewed journal published by Mary Ann Liebert, Inc. (http://www.liebertpub.com). The entire issue is available free online at http://www.liebertpub.com/zeb
Guest Editors Steven D. Leach, MD, the Paul K. Neumann Professor in Pancreatic Cancer and Professor of Surgery, Oncology and Cell Biology at Johns Hopkins University (Baltimore, MD) and A. Thomas Look, MD, Professor, Department of Pediatrics, Harvard Medical School, and Vice-Chair for Research Pediatric Oncology, Dana Farber Cancer Institute (Boston, MA), have compiled a comprehensive collection of papers that describe current approaches for modeling human cancer in zebrafish, studying tissue remodeling in zebrafish embryos, and understanding the genes, genetic control elements, and repair pathways involved in the development and metastasis of tumors.
A particular advantage of using zebrafish to study cancer biology is the ability to transplant human tumors into the fish using well-established methods. Authors Leonard Zon, PhD, and Alison Taylor, PhD, from Harvard Medical School and Children’s Hospital Boston present the concepts and techniques relevant to zebrafish transplantation assays. They describe how tumor transplantation has been used to study leukemia, rhabdomyosarcoma, and melanoma in the paper “Zebrafish Tumor Assays: The State of Transplantation.”
The molecular basis for cancers affecting human germ cells is poorly understood, impeding efforts to identify more effective and targeted treatments. In the paper entitled “Identification of a Heritable Model of Testicular Germ Cell Tumor in the Zebrafish,” authors Joanie Neumann, Jennifer Dhepard Dovey, Garvin Chandler, Liliana Carbajal, and James Amatruda, describe the development of a zebrafish model that carries a genetic mutation making the fish highly susceptible to the development of testicular tumors. This model system can be used to test new approaches to therapy for testicular cancer.
Jun Chen and Jinrong Peng, from Zhejian University (China), describe the use of transgenic zebrafish to understand the roles that different naturally occurring forms of the tumor suppressor gene p53 play in regulating cell cycle, metabolism, organ development, and cell aging and death. Their paper “p53 Isoform Δ113p53 in Zebrafish” discusses the potential use of this particular p53 isoform for characterizing factors in the p53 pathway and screening for novel cancer therapies.
Noting the “relative ease and low costs of transgenesis”—putting human genes into zebrafish—and the unique benefits of working with zebrafish, especially related to imaging, genetics, and transplantation, Dr. Leach predicts that, “Future zebrafish cancer research exploiting these fundamental advantages will be especially likely to generate novel insights not achievable using other model systems,” in his Introduction to the issue entitled, “Pisces and Cancer: The Stars Align.”
###
Zebrafish is an authoritative peer-reviewed journal published quarterly in print and online. This is the only peer-reviewed journal to focus on the zebrafish and other aquarium fish species as models for the study of vertebrate development, evolution, toxicology, and human disease. Tables of contents and a free sample issue may be viewed online at http://www.liebertonline.com/zeb.
Mary Ann Liebert, Inc., is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including DNA and Cell Biology, Stem Cells and Development, and Cloning and Stem Cells. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 60 journals, books, and newsmagazines is available at http://www.liebertpub.com.
Contact: Vicki Cohn
.(JavaScript must be enabled to view this email address)
914-740-2156
Mary Ann Liebert, Inc./Genetic Engineering News
Print Version
Tell-a-Friend comments powered by Disqus
